INDEX

Note: Italicized page locators refer to figures or tables in exhibits.

AAMC. See Association of American Medical Colleges
Aaron, Henry: behavior, 166; utility theory, 368
Abel-Smith, Brian, 495
Abramson, J., 271
ACA. See Affordable Care Act
Access (to care), 329–30, 372–76, 475–76, 479; backlash and concerns about, 201–4; self-reported measures of, in 2013, 478
Accountable care organizations (ACOs), 192, 335, 374, 400; description of, 199; market power, 212; preliminary cost containment studies, 201; quality evaluations, 205
Actuarially fair insurance, 87, 88
Aday, Lu Ann, 366
Adderall, 268
Addiction: market behaviors and, 169
ADHD. See Attention-deficit hyperactivity disorder
Administrative costs, 396, 397
Advanced practice nurses, 284, 338
Adverse events: hospital ownership and, 239; reducing, higher registered nurse–to-patient ratios and, 332, 333
Adverse selection, 130–31, 455, 500n2
Advertising, 167, 170–71
Aetna: merger with Prudential, 217
Affordable Care Act, 3, 90, 91, 162, 171, 225, 325, 344, 345, 400, 469, 484; access to healthcare and, 372–76; accountable care organizations and, 199; choice of plans, 496; Community Health Centers and, 330; cost comparisons prohibition, 414; declining uninsured rates with, 454, 475; deductibles and, 128, 463; enactment of, 373; essential health services and, 463; exchanges, 204; expanded access to care under, 316, 327, 334; goals of, 375; healthcare demand and, 313; health industry and, 272; main features of, 373–75; managed competition and, 405; Medicaid and, 374, 375; Medicare and, 374; Medicare fee schedules for primary care, 337; Medicare payment rate cuts and, 224; movement away from fee-for-service, 497; narrow networks, 130; Oregon study, 105; patient cost sharing and, 405; preventive services, 126, 133, 138n24; price elasticity of demand and, 92
African Americans: physician choice of geographic location and, 320; underrepresentation in health professions, 314
Age: physician choice of geographic location and, 320
Agency for Healthcare Research and Quality, 195, 407, 414, 445, 469, 498
Agency relationship: between physicians and patients, 182
Agents, 62
Aggregate demand, 16
Aggregate supply, 31
AHA. See American Hospital Association
AHRQ. See Agency for Healthcare Research and Quality
Aiken, L. H., 339
Akerlof, George, 82
Alcohol abuse: annual economic costs of, in United States, 401
Allocation: distribution dealt with concurrently, 161–62; formula, 355; methods, categories of, 363–64
Allocation rule, 366
Allocative efficiency, 42, 47, 169
Allopathic physicians: increase in, 312
All-payer system, 225, 410, 456, 494, 495; coordination of payers and, 456–57; market power and, 391; monopsonistic power and, 406; provider payment and, 393
Altenstetter, C., 451
Alternative goods, 16, 17
Alternative Quality Contract accountable care organization (Massachusetts), 201, 205
Altman, S. H., 225
Altruism: equity vs., 348–49
Ambulatory care centers, 252
Ambulatory surgical centers: ownership of, 233
Amenable mortality, 483–84, 485
American Hospital Association: Annual Survey, 227; Hospital Statistics, 227
American Indians: underrepresentation in health professions, 314
American Medical Association, 211
American Nurses Credentialing Center: Magnet Recognition, 338
American Recovery and Reinvestment Act, 337
Andersen, Ronald, 366
Anderson, Gerard, 390, 391
Anesthesiologists: supply, 308
Angell, M., 256, 261, 262, 279
Angiotensin-converting enzyme inhibitors, 261
Antitrust laws and regulations, 38, 208
Any-willing-provider laws, 201
APNs. See Advanced practice nurses
Arc elasticity, 45n4
Ariely, D., 81
Aron-Dine, A., 104
Aronson, Elliot, 81, 167
ARRA. See American Recovery and Reinvestment Act
Arrow, Kenneth: health, 365; possibility theorem, 43; social welfare, 356; trustworthy behavior, 241
ASCs. See Ambulatory surgical centers
Association of American Medical Colleges, 325, 326
Assumptions: of competitive model, 47–49, 48; importance of, 48
Asymmetric information, 67, 135, 136n6
Atherly, A., 91
Attention-deficit hyperactivity disorder: in France, 267, 268; rate of, in United States, 267, 268
Auerbach, D., 91, 326, 329
Australia: amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; citizens’ juries in, 376; comparative effectiveness research, 469; cost-effectiveness analysis in, 407; cost-sharing requirements, 464; decline in total hospital beds, 466; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 481, 482; health expenditures as
Index

Austria: healthcare expenditures, 482

Authorizations, 197

Autonomy: physicians and, 322

Average costs: explanation, 26; long-run relationship, 28, 29; short-run relationship, 28, 28–29, 29

Average fixed costs, 26–27

Average total cost curve, 31

Average total costs, 27, 31

Average variable costs, 27, 31

Avnaim-Pesso, L., 80

Ayanian, J. Z., 108

Backward-bending supply curve, 188, 188–89, 228n1, 302, 305, 341n6

Baicker, K., 105, 106, 332

Baker, C., 246

Balanced Budget Act of 1997, 317

Bamezai, A., 223

Barer, M. L., 466

Barnes, A., 73

Bartlett, J. C., 309

Bator, Francis, 143

Bazemore, A. W., 328

Bazzoli, G., 243

Bear, H., 227

Becker, Gary, 81, 166

Begun, J. W., 246

Behavioral economics, 60, 81; cognitive biases, 77–80; definition of, 76; focus of, 64; of health, 123

Behaviors: environment, 167–70; gaming, 193; influencing, 122–23; maximizing, 166

Belgium: healthcare expenditures, 482

Benartzi, Shlomo, 82, 83

Benefits: discounting, 433–35

Benefit-to-cost ratios, 446

Bennett, K., 319

Bentham, Jeremy, 8, 347, 358

Best practices, 382; expenditures and deviation from, 398–99

Beta-blockers, 257, 261

Beveridge, William, 455

Bhattacharya, J., 467

BHP. See Bureau of Health Professions

Blackstone, E., 250

Blendon, Robert, 372

Bloom, M. G., 134

“Blockbuster” drugs: new, lack of, 388

Blood glucose medications, 258

Blue Cross and Blue Shield of Texas, 399

Bognanno, M. F., 309

Bonuses, 199

Born, P., 241

Boulding, Kenneth, 166

Bueno, Kenneth, 166

Brennan, T. A., 277

Brody, H., 258

Buchmueller, T. C., 91, 130

Budget constraint, 11–12, 12

Budget controls, 469

Budgets: global, 120

Budig, P., 287

Buerhaus, P. I., 326, 329

Bunten, M. B., 132

Burden of illness (or disease), 415

Bureau of Health Professions, 312; forecasting model, 326; projections, 328, 329

Copy and distribution of this PDF is prohibited without written permission.
For permission, please contact Copyright Clearance Center at www.copyright.com
Index

Burnout: physicians and, 321
Busse, R., 451
Butler, Timothy, 226

“Cadillac tax,” 374
Calcium channel blockers, 257
Campaign finance reform, 279
Campbell, J. C., 456, 473
Camus, Albert, 82
Canada: administrative costs, 396, 397; adult obesity rates, 488; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; Beveridge-style system, 455; cost sharing, 463–64; decline in total hospital beds, 466; economic analyses, 469; expenditure caps, 472–73; fee-for-service, 497; generalists and specialists as percentage of all doctors, in 2011, 397; global budgets, 470; healthcare expenditures, 387, 481, 482; hospital payment system, 410; income inequality, 347; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 486; medical technology use, 467, 468; negotiation of physician fees, 391, 393; patient cost sharing, 404; per capita health expenditures, in 2011, 386; physician fee schedule, 471; physician payment rates, 187–88; physician supply, 466–67; private health insurance, 459; public financing in, 384; public programs, 476; public share of expenditures on medical services, in 2011, 388; regional administration, 458; service wait times, 476, 479, 492; single-payer system, 49, 393, 406; smoking rates, 487, 488; supplemental insurance, 501n4; unit prices, 391, 392; universal coverage, 92, 453; user charges, 494; utilization rates, 479, 480; World Health Organization assessment, 474
Candide (Voltaire), 60
Cantril, Hadley, 148
Capabilities: equalizing, 359–61; health and, 365; resource allocation and, 361–64
Capital, 292; costs, 426; medical technology and, 467–69
Capital–labor decision, 294–96; in the long run, imperfect substitutes, 294, 295; in the long run, perfect complements, 296, 296; in the long run, perfect substitutes, 294, 295
Capital–labor substitution, 294–96, 297
Capitation, 120, 193, 198, 199, 200, 201, 399–400, 408, 409, 473, 497, 504
Capture theory, 50
Carbon taxes, 141
Cardiac technologies: healthcare expenditures and, 394
Cardinal utility, 347
Care coordination: mechanisms in, 335
Care labor: gender-based inequality and, 358–59
Carve-outs: consumer-driven health plan products, 132, 133
Case management, 197
CBA. See Cost–benefit analysis
CBO. See Congressional Budget Office
CDHPs. See Consumer-directed health plans
CEA. See Cost-effectiveness analysis
Celebrex, 259, 391
Cellini, S. R., 439
Centers for Disease Control and Prevention, 498
Centers for Medicare & Medicaid Services, 163, 194, 196, 199, 233, 275, 498
CER. See Comparative effectiveness research
Certificate-of-need laws, 229n16, 269, 274, 275
Chance nodes: in decision trees, 435, 436
Chandra, A., 332
Charity care, 237, 238, 243, 244, 245, 273
CHCs. See Community Health Centers
Chen, H., 243
Chen, V. K., 416
Chernow, M. E., 70, 101
Chiropractors, 286
Cholesterol guidelines, 258
Christianson, J. B., 132
Chronic care measures, 486
Chronic illness, 138n27
Churning, 193, 389, 399–400, 497
Cigna, 199
Claritin, 269
Classical utilitarianism, 8; assumptions in, 9; equality, 357
Claxton, G., 244, 245, 274
Clinical nurse specialists, 284
Clinical Practice Guidelines We Can Trust (Institute of Medicine), 195
Clinical trials, 253
Clinton administration: health reform proposal, 272
CMS. See Centers for Medicare & Medicaid Services
Coase, Ronald, 175–76n1
Coase theorem, 175n1
COGME. See Council on Graduate Medical Education
Cognitive dissonance, 81–82
Coinsurance, 68, 404, 462; demand elasticity relationship, 124–25; price elasticity relationship, 124–26; public health model, 125–26; utilization and, 97–98; welfare loss and, 117, 120–23, 121
Collard, David, 370
Collusion, 206
Commercialization of healthcare, 265–72; commodification, 265–66; corporatization, 266; effects of, 270–72; medicalization, 266; pharmaceuticalization, 266–67; policy measures, 279; in United States, 269
Commitment: definition of, 368; individual behavior and, 367–69; sympathy vs., 368
Commodification, 265–66, 269
Commodities, 452
Commonwealth Fund, 474, 475, 485; quality system rankings, in 2013, 485, 487
Communitarianism, 376
Community benefit, 243–45
Community Health Centers, 314, 330, 333
Community hospitals: market power trends, 209, 209–12, 210
Community sense: health system perceptions and, 379n18
Comparative effectiveness research, 407, 414, 468, 469, 504
Competitive equilibrium, 42, 43
Competitive firms: choosing profit-maximizing level of output, 30, 31; pricing and output decisions by, 212, 214; pricing and output decisions by, with demand inducement, 213, 214
Competitive market, 169, 179, 187
Competitive model: assumptions of, 47–49, 48; concern about status and rank, 142–43, 151; demand curves, 15–18; economy as a whole, 39–43; equilibrium, 33–36; equilibrium for a monopolist, 36–39; income and substitution effects, 18, 19, 20; production, costs, and supply, 21–33; supply curve, 30–33; traditional, 7–43; utility, 8–14
Complementarities, 286
Complements: definition of, 16; example of, 18; negative cross-price elasticities, 21
Component enumeration, 229n17
Computerized tomography scanners, 252, 467, 468, 501n5
Congressional Budget Office, 375
CON laws. See Certificate-of-need laws
Conrad, P., 267
Consistency, 80
Constant returns to scale, 28
Consumer: counterfactual issues, 74–76; maximization of utility by, 8, 9; price transparency and, 402–4, 403; protection, 74; rationality, 13, 80–83, 90–91; sovereignty, 369; tastes, 169; theory, 14
Consumer choice: adverse consequences, 496–97; counterfactual questions, 74–76; elimination of, 172; information and, 65–74; libertarian view, 63; paternalistic laws, 64–65; sanctity of, 168; social welfare and, 61–62, 83–84, 168; too much argument, 172–75; utility maximization and, 62–74
Consumer-directed health plans, 60, 117, 128, 131–35; concerns related to, 134–35; income and, 133–34; types of, 131–32
Consumer groups, 163
Consumerism, 67
Consumer optimum, 13–14, 14, 18
Consumer Reports, 241
Consumer surplus, 109–10; derivation of, 109, 110; total, 109
Consumption externalities, 139; competition assumption, 141; concern about others, 158–65; concern about status, 142–58
Contingent valuation example, 433
Contingent value, 431
Contract curve, 40, 41
Conversion factor, 471
Conversions: encouraging/discouraging, 273; of private and public nonprofit organizations, 234
“Cookie jar effect,” 136n12
Cookson, R., 359
Cooper, R. A., 327, 328
Cooper model, 326
Coordinated payments, 494–96
Copayments, 68, 192, 462; prescription drugs, 404; reduced physician payment rates and, 188; for specialist office visits, 404
Coronary care: cost-effectiveness and implementation of practices for, 270, 270
Corporatization, 266, 269
Cost–benefit analysis, 413, 415, 416, 419–21, 422, 425; conducting, 444–46; example of, 421; in hospitals, 414; limitations with, 420, 446; measurement of costs and effects in, 425; present value of future costs and benefits, 435; steps in, 439, 440
Cost-consequence analysis, 415, 416, 418, 421, 422; measurement of costs and effects in, 425
Cost containment strategies, 381. See also Demand-side cost containment methods; Supply-side cost containment methods; organizing, 402; prevention, health promotion, and, 252; primary care physicians and, 395–96
Cost-effectiveness analysis, 403, 406–7, 413, 415, 416, 421, 422, 425, 437, 449; conducting, 440–44; effectiveness measure and, 427; example, 419; limitations with, 428, 446; measurement of costs and effects in, 425; objective of, 418; steps in, 439, 440
Cost identification, 416, 416
Cost-minimization analysis, 416, 416; disadvantage with, 418; example, 417
Cost of Diabetes Model, 417
Cost-of-illness analysis: example, 417; purpose of, 415, 416
Cost(s): average, 26–27; of capital, 281n6; direct, 426, 427; direct nonmedical, 426, 427; discounting, 433–35; economic, 32; economic evaluation of, 427; expenditures vs., 382; fixed, 26, 27, 426; of human capital development, 303; indirect, 426, 427; intangible, 426, 427; malpractice, 400; marginal, 27; measurement of, in economic evaluation, 425; measuring, 426–27; opportunity, 32, 160, 281n6, 381, 434; total, 26, 27, 27; variable, 26, 27, 426
Cost sharing. See Patient cost sharing
Cost shifting, 224, 406, 457; elimination of, 225; physician, 224; policies, 224–25; studies on, 223–24; theory, 219–23
Costs of capital, 281n6
Cost–utility analysis, 415, 419, 421, 422, 425, 428, 429, 449; conducting, 444; example of, 420; incremental cost-effectiveness ratio of, 444, 445; limitations with, 444, 446; measurement of costs and effects in, 425; steps in, 439, 440
Council on Graduate Medical Education, 325, 326
Counterfactual questions, 74–76, 504
Cournot duopoly equilibrium, 229n10
COX-2 inhibitors, 261
Cross-price elasticity: calculating, 45n5
Cross-price elasticity of demand: definition of, 21; positive and negative, 21
CUA. See Cost–utility analysis
Culyer, A. J.: equity, 348; health status, 365, 366
Curative services: preventive services vs., 401
Currie, J., 360
Cutler, D. M., 130, 131, 210, 211, 395
CV. See Contingent value
Daly, George, 370
Daly, M. C., 154
DALYs. See Disability-adjusted life years
Danger, K. L., 216
Daniel, D., 71
Daniels, Norman, 351, 377
Danziger, S., 80
Darrow, J. J., 259
Dartmouth Atlas, 398
Darwin, Charles, 140
Davis, K. K., 485
“Death panels,” 468
Death spiral, 130, 131
Deaton, A., 156
Decision analysis, 428, 435–37, 449
Decision fatigue, 79–80
Decision nodes: in decision trees, 435, 436; in Markov decision model, 438
Decision trees, 435–37; analysis example, 436, 437; economic evaluation, 423; simple, 436
Deductibles, 68, 96, 128, 192, 404, 462; in consumer-directed health plans, 131, 132, 133; in high-deductible health plans, 404–5; in preferred provider organizations, 135
Default system: organ donation and, 77; savings accounts and, 83
Defensive medicine, 400
Deily, M. E., 246
Dekker Committee (Netherlands), 460
Delattre, E., 187
Demand: aggregate, 16; definition of, 59; determinants of, 17; elasticities of, 20–21, 33; for health, 17, 84–86; for healthcare, 307, 313, 316; for healthcare labor, 309, 309, 316–17; for healthcare labor supply, 317–25; for health insurance, 86–92, 88, 89; for health services, 92–128; income and, 17; marginal revenue and, 37; Medicare payment rates and, 187; need vs., 308, 309, 310; optimizing for healthcare workforce, 334–35; price and, 17–18; price elasticity of, 20; short-run equilibrium, 33, 34, 34; substitution effect, 18, 20; supply relationship, 181–205; wages and, 296, 309

Demand curve: assumptions, 15; derivations, 15, 15–17, 16; elasticity of demand for labor, 298; functions, 15–18; interpretation of, 113, 117–18; slope, 46n8

Demand for labor, 283; derivation of, 298, 299; elasticity of, conditions in, 298–300; labor substitutes and complements, 296–97; in the long run, 292, 294–96; in the short run, 291–93

Demand-for-leisure model, 301, 301

Demand inducement: direct-to-consumer drug advertisements and, 256; physician payment rates, 187–90; by physicians, 182, 183–84, 191–92, 197; physician-to-population ratios and prices, 185–86; physician-to-population ratios and utilization, 184–85, 185; research on, 190–91; by suppliers, 184–85; testing for, 184–90

Demand-side cost containment methods: managed competition, 403, 405; patient cost sharing, 403, 404–5; price transparency, 402–4, 403

Demand-side policies: healthcare services and, 120

Denmark: hospital system in, 465

Dental insurance, 90

Dental services: price elasticities and, 125

Department of Health and Human Services: Affordable Care Act and essential health services, 463

Department of Justice, 208, 211, 212

Desai, K. R., 248

Devereaux, P. J., 239

Diabetes: economic burden of, 415, 417; guidelines, 239

Diagnostic imaging, 252

Dialysis centers, 252

Dialysis units: for-profit ownership and, 232, 233, 240; quality studies, 240–41; trustworthy behavior, 242

Dickens, William, 82

Difference principle, 349

Diminishing marginal productivity, 22, 22, 26, 292, 294

Diminishing marginal utility, 8

Direct medical costs, 426, 427

Direct nonmedical costs, 426, 427

Direct-to-consumer advertising, 269, 276; criticisms of, 256; drug utilization and, 256–57; regulation, 255–56

Disability-adjusted life years, 429, 430; cost–utility analyses and, 444; quality-of-life years vs., 432

Disadvantaged population, 70, 330. See also Uninsured population

Discounting, 449; costs and benefits, 433–35

Discount rates, 434
Discrepancies: physician dissatisfaction and, 322
Disease: economic burden of, 415; healthcare expenditures and focus on, 401; management, 197, 407
“Disease mongering,” 258
Disecomy of scale, 28, 29
Distribution: allocation dealt concurrently with, 161–62
Distribution of income, 152–58
Distributive justice, 159
Diuretics, 257
Diversity: improving, 315; in nursing profession, 339
Doctors of medicine (MDs), 284, 341n4
Doctors of osteopathy (DOs), 284, 341n4
DOJ. See Department of Justice
Donor desire, 369–70
Dormont, B., 187
“Doughnut hole”: health reimbursement arrangements and, 132
Dovey, S., 327
Dowd, Bryan: consumer information, 65; price–demand relationship, 91
Dranove, D., 218
DRGs. See Diagnosis-related groups
DRG weight, 194, 276
Drug abuse: annual economic costs of, in United States, 401
Drummond, M. F., 415, 426, 446, 447, 469
DTC advertising. See Direct-to-consumer advertising
Dual process theory, 76–77
Duesenberry, John, 145
Duopoly, 36
Dupuit, Jules, 109
Dworkin, Ronald, 358
Easterlin, Richard, 145, 146, 148
EBP. See Evidence-based practice
Economic burden, 415
Economic costs, 32
Economic efficiency, 24, 158, 161
Economic evaluation in healthcare: components of, 424; political opposition to, 414; spectrum of, 416; types of, 415–16, 418–21
Economic evaluation(s): assessing, checklist for, 446, 447; common measures and tools of, 422, 425–39, 449; conducting, 439–46; of costs and viewpoints, 427, 427; decision trees in, 423, 435–37, 436, 437; definition of, 413; denial of care and, 448; discounting costs and benefits, 433–35; effectiveness measures in, 427–28; full, 420–21, 422, 449; guidelines for, 446–47, 449; hierarchies of evidence for, 441; importance of, 415; issues in, 446–48; limitations with, 448; Markov models in, 437, 438; measuring costs in, 425, 426–27; partial, 413, 420, 449; quality-of-life measures in, 428–30; resources saved, 432–33; sensitivity analysis in, 437–39; uncertainty in, 446; validity of results, 446; willingness to pay, 430–32
Economic profits, 32
Economics: as distinct from other social sciences, 166
Economics of health: reconsidering, reasons for, 3–4, 5
Economics of Welfare (Pigou), 371
Economic theory: misapplication of, 4; of regulation, 50, 51
Economies of scale, 22; concentration, 218; conversions and, 234; definition, 28; in horizontal integration, 207; hospitals and, 465; increasing returns to scale, 225–27; long-run costs and, 27–30; monopoly, 207; physicians and, 211; in vertical integration, 207–8
Edgeworth, Francis, 39
Edgeworth box, 39, 41, 159, 345, 346
Education: health and, 85–86
Effectiveness measures, 427–28
Efficacy: drug testing for, 260
Efficiency, 345, 504; allocative, 42, 47, 169; cost sharing, 122; criteria, 366; economic, 24, 158, 161; reforms and, 497; technical, 24
Egalitarian societies: life spans in, 155
Eggleston, K., 239
Einav, L., 104
Elasticity. See also Cross-price elasticity of demand: arc, 45n4; of demand, 20–21, 33; of demand for labor, 298–300, 341n9; determinants, 20–21; drug expenditures, 277; formulas, 44–45n4; income elasticity of demand, 21; of labor supply, 304–5; positive cross-price elasticities, 21; of registered nurse supply, 324; supply, 33; unitary, 298
Elbel, B., 69
Eliat, E., 225
Ellis, R. P., 402
Ellis, Randall, 117, 122, 124
Ellwood, Paul, 464
Emanuel, E. J., 357, 363
Emergency care: Oregon study, 105
Emergency department (ED) utilization: access-to-care issues, 330
Empathy: egalitarian society and, 154
Employment: equilibrium level of, 293
Employment-based health insurance, 252, 306; price–demand relationship, 91; tax issues, 92
Endotracheal tubes: silver-coated vs. uncoated, study of, 418, 419
England. See United Kingdom
England, P., 287
Enthoven, Alain: government role, 4; managed competition, 405, 460
“Entitlement theory” (Nozick), 353, 354
EQ-5D scales, 430; attributes in, 429; health state evaluations, 431
Equality: role of, 356–59
Equal treatment, 363, 363
Equilibrium: analysis, 39–41; competitive, 42, 43; in competitive market, 33–36; labor market, 305; level of employment, 293; long-run, 35, 35–36; of market, 7; in monopoly, 36–39; regulators, 54–55n6; short-run, 33–34, 34; for single-price monopolist, 38; through trading, 346
Equity, 344, 345, 347, 378, 504; access to health services and, 366; altruism vs., 348–49; of care, physician supply and, 330–32; enhanced, public programs and, 463; horizontal, 357, 494; Pareto optimality, social welfare, and, 41–43; patient cost sharing and, 122; progressive revenue sources and, 489; redistribution of wealth and, 41; reforms and, 497; role of, 356–59; vertical, 357
Esposto, A. G., 248
ETTs. See Endotracheal tubes
Europe: happiness levels study, 146, 148; health policy in, 162
European Observatory on Health Systems and Policies, 474
Evans, Robert: commodities, 452; patient cost sharing, 121; social standing and health, 153; universal coverage, 490; welfare burden, 112
Everything for Sale: The Virtue and Limits of Markets (Kuttner), 54n2
Evidence-based practice, 192, 195
Expenditures: costs vs., 382
Experimental designs: shortcomings in, 101
Externalities: of consumption, 139–65; market performance role, 139–42; types of, 139–40
External validity, 101, 102
Extra-welfarism, 348, 366, 379n12
Fahs, Marianne, 137n15
“Fair innings” argument, 379n16
Fairness, 162, 345, 348
Favorable selection of patients, 129–30
FDA. See Food and Drug Administration
FDCA. See Food, Drug, and Cosmetic Act
Federal Trade Commission, 66, 208, 211, 212
Fee-for-service, 409; advantages of, 497; churning resulting from, 399–400; cost increases with, 471; movement away from, 193, 497
Feldman, Roger, 91; consumer-driven health plan study, 132; consumer information, 65, 66; market concentration, 217
Feldstein, Paul: demand theory, 87; government role, 503
Ferris, J. M., 244
FFS. See Fee-for-service
Figueras, J., 464
Filson, D., 278
Final outcomes, 428
Financial incentives, 127, 138n26, 202, 409, 466, 470
Finkelstein, A., 92, 104
Finkler, Stephen, 226
Fisher, E. S., 332, 335
Fixed costs, 26, 27, 426
Fleming, Gretchen, 366
Flood, C. M., 452
“Focused factory” effect, 249
Folbre, N., 287
Food, Drug, and Cosmetic Act, 253
Food and Drug Administration, 253, 254, 255, 257, 276, 277, 278; Center for Drug Evaluation and Research, 260
Forecasting models, 325–27; caveat, 327; physicians and nurses, 325, 326, 340
For-profit healthcare: origination of, 234
For-profit organizations: quality reviews, 238–41; taxes and, 235
Forrest, C. B., 202, 330, 331
France: adult obesity rates, 488; all-payer system, 385, 393, 456; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; Bismarck-style system, 455; cost-sharing exemptions, 494; cost-sharing requirements, 464; fixed fee-for-service conditions in, 187; funding sources, 455; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 481, 482; health expenditures as share of gross domestic product, 2011, 387; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 486; medical technology use, 468; patient cost sharing in, 404; per capita health expenditures, 2011, 386, 386; public programs, 476; public share of expenditures on medical services, 2011, 388; service wait times, 476; smoking rates, 488; supplemental insurance, 501n4; universal coverage in, 454; user charges, 494; utilization rates, 480; World Health Organization assessment, 474
Frank, Robert: on individual choice, 63–64; progressive consumption tax, 151–52, 176–77n6; relative status, 143, 144–45; social welfare, 83
Franzini, L., 399
Free choice: subjective well-being and, 147, 149
Freedom-of-choice laws, 201
Frick, K., 240, 242
Friedberg, M. W., 395
Friedman, B., 246
Friedman, E., 332
Friedman, Milton: consumer choice, 168; demand theory, 87; preferences, 166; price focus, 122
FTC. See Federal Trade Commission
Fuhr, J., Jr., 250
Future values: discounting, 434
Gabe, J., 266, 267
GAD. See Generalized anxiety disorder
Gage, H., 418
Gagnon, M., 263
Game theory, 228–29n10
Gaming behaviors: monitoring, 193
Garg, P., 240
Gawande, Atul: regional variation in medical services, 398–99
GDP. See Gross domestic product
GDP deflator: US healthcare expenditures, 382, 383
Gender: nursing retention and, 324; physician choice of geographic location and, 320; physician work hours and, 321
General equilibrium analysis, 39, 40
Generalized anxiety disorder, 269
Generic drugs, 254, 388
Germany: adult obesity rates, 488; all-payer system, 385, 393, 406; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; Bismarck-style system, 455; cost-sharing requirements, 464; decline in total hospital beds, 466; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 481, 482; healthcare reform in, 451; health expenditures as share of gross domestic product, in 2011, 387; health system performance, 500; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 486; managed competition, 460; medical technology use, 468; opt-out capabilities, 495; per capita health expenditures, in 2011, 386; physician fee schedule, 471, 473; private insurance, 384, 457, 458; public programs, 475, 476; public share of expenditures on medical services, in 2011, 388; service wait times, 476; sickness funds, 456, 457; smoking rates, 488; “substitute funds,” 457; uninsurance rates in, 375; uninsured individuals in, 454; universal coverage in, 453; user charges, 494; utilization rates, 479, 480; World Health Organization assessment, 474
Giertz, Fred, 370
Giffen goods, 44n3
Giffen’s paradox, 44n3
Gilmer, T., 89
Ginsburg, P. B., 221
Gintis, Herbert, 178n25
GlaxoSmithKline, 269
Glied, S. A., 391
Global budgets, 120, 192, 200, 470–71, 491, 504; cost containment and, 403, 410; in Ontario, 393
GME. See Graduate medical education
GMENAC. See Graduate Medical Education National Advisory Committee
Goldman, D., 106
Goodman, B., 257
Goodman, D. C., 326, 335
Goods: alternative, 16, 17; inferior, 17, 18, 44n3; normal, 17, 18
Goods altruism, 368
Goods externality, 370
Goods over cash provision: desires of donors and, 369–70; ensuring sufficient donations, 370–71; improving productivity, 371–72
Gottfried, J., 203
Government: alternative roles for, in healthcare sector, 451–73, 452, 453; challenges, 50; failure, 49–52, 53, 54n4; health education and, 170–72; hospitals, 247; intervention, 47, 142; lessons on role of, in healthcare systems, 487–500; market vs., 52–53; Nozick on just role of, 353; oversight, 499–500; as purchaser of services, 490–91; role of, 4, 344, 503
Government Accountability Office, 248
Goyal, M., 64
Graaff, J. de V., 47, 160
Graddy, E. A., 244
Graduate medical education: funding cap, 334; primary care promotion, 335, 336
Graduate Medical Education National Advisory Committee, 325, 326
Gray, B. H., 235, 239, 240, 243, 274
Great Britain. See United Kingdom
Green, Ronald, 351
Greene, J., 71, 117, 134
Gross domestic product, 326; health expenditures as share of, selected countries, in 2011, 386, 387; Netherlands health spending as proportion of, 462; per capita, health expenditures per capita and, 481, 482; sustainable growth rate formula and, 472; US healthcare expenditures, 382, 383, 384
Grossman, Michael, 84, 85
Group Health Cooperative of Puget Sound, 241
Group practices, 211
Gruber, J., 91, 184
Grumbach, K., 315, 326
GSK. See GlaxoSmithKline
Hardin, Garrett, 140
Harding, A., 491
Harvard University health plans: cost savings, adverse selection, and, 130–31
Hausman, Daniel, 345
Hayek, Friedrich, 62, 63
HCR ManorCare, 211
Health: behavioral economics of, 123; behaviors, 487; at birth, life opportunities and, 360–61; demand for, 17; demands, 84–86; distribution of income relationship, 152–58; education and, 85–86; equity, justice, and, 365–72; extension of Rawls’s theory to, 351; as key capability, 360; misapplication of economic theory to, 4; relative deprivation and, 145–52; social determinants of, addressing, 360, 377; status, 366
Healthcare. See also Economic evaluation(s); access to, as social primary good, 351; commercialization of, 265–72; demand for, 307, 313, 316; for-profit ownership in, 232–34; outcomes, 483–87; problematic nature of markets in, 49; societal choices in, 452
Healthcare costs: healthcare expenditures vs., 382
Healthcare delivery: coordinated prevention approach in, 334–35; health workforce resources and, 316–17; system design and financing, 316
Healthcare Effectiveness Data and Information Set, 69, 241
Healthcare expenditures, 90, 119, 270–71, 332–33, 381–411, 480–82, 481, 482; alternative methods for control of, 402–10; churning of services and, 399–400; deviation from best practices and, 398–99; disease vs. wellness focus and, 401; healthcare costs vs., 382; international comparisons, 384–88, 386, 387, 388; lack of market power among purchasers of services, 391, 393–94; medical malpractice and, 400; medical technologies, specialization, and, 394–96; overview, 381–82; population ill health and, 400–491; primary factors responsible for, 388–91, 393–401; private health insurance cost administration, 396–98; trends and, 382, 384–88; in United States, 381–82, 383; unit prices and, 389–91, 393; waste in the system, 381
Healthcare labor supply: factors affecting, 317–25
Healthcare occupations: educational requirements, employment, wages, and income, in 2013, 285
Healthcare reform: equity, efficiency, and, 497; in Netherlands, 460–62; reliance on market forces and, 3; in United States, 373
Healthcare services: access, 366; demand elasticities for, determining, 20; demand for, 92–128; demand-side policies, 120; marginal utility, 114, 116; medical effectiveness groupings, 115, 116; Oregon Health Insurance Experiment, 104–6; physical health results, Baicker and colleagues study, 106, 107; RAND Health Insurance Experiment, 93–104; rationing, 163–64, 366; regional variation in provision of, 398; supply-side policies, 120, 122–23; utilization of, 102–3; wasteful use, 119–20
Healthcare workforce: access to care, 329–30; active in United States, 284, 286–87, 289–90; adequacy of, 283, 310–15; assessing demand and supply of, 310–11; competition, 305; disparities in, 314–15; educational investment, 303–4, 318; educational requirements, 284, 285; education and income correlation, 287; expenditures and, 332–33; forecasting models, 325–27, 340; forecasts, 308–9, 327–29; future adequacy, 327–29; future expectations of demand, supply, and wages, 308, 308–9; inactive or nonparticipants, 311; international issues, 283–84, 311, 312, 318, 323; introduction to, 283–84; labor–labor substitution, 296; physician compensation by specialty, in 2013, 288; physician supply, 310, 311–13; policies for optimization, 334–39, 340; quality of care, 330–32; registered nurse supply, 307, 310, 313–14; shortages/
surpluses and expenditures, 305, 332–33; supply of, 179; unlicensed nonprofessionals, 286, 287; wage/income, 285, 287, 289

Health education: government-sponsored, 170–72

Health Grades, 74

Health insurance: adverse selection, 130–31, 455; affordable, 377; cost-sharing products, 128–35; demand for, 86–92, 88, 89; employer-based, 252, 306; extension of, in United States, 3; for-profit ownership and, 233; high-deductible policy, 131; industry consolidation, 211; literacy, 127; premium death spiral, 130, 131; price elasticity of demand, 91, 124–28; selection bias and, 129; state mandates, 163, 177n16; theory of the second best and, 53–54n2; value-based insurance design, 127–28; welfare loss argument, 109–19, 129

Health Insurance Act (Netherlands), 461

Health insurance exchanges: Affordable Care Act, narrow networks, and, 130

Health Insurance Experiment (RAND), 60, 93–104

Health insurance industry: political power of, 272

Health Justice (Venkatapuram), 360

Health maintenance organizations, 198, 199, 201, 205, 213, 397, 408; capitated payment methods, 399; cost containment, 120, 205; for-profit ownership and, 232, 233; pay for performance, 201; penetration, 204, 217; physician payment, 408; plan quality, 203; preventive services, 204; specialist referrals, 464

Health outcomes: definition of, 156

Health plans: competition among, 462; quality studies, 241; report cards, 69–72; risk adjustment of payments, 138n27; trustworthiness of, 242

Health policy: access-centered vs. health-centered views and, 366; access issues, 162; challenges, 505; education, 170–72; in Europe, 162; mandates, 163; market power implications, 218–19; social values and, 163; subsidization and, 162; technology coverage, 164–65; tools, 504; in United States, 162

Health program benefits: monetizing, 431–32

Health reimbursement arrangements, 131–32

Health Resources and Services Administration, 330

Health savings accounts, 128–31, 138n26, 192

Health-sector costs: in economic evaluations, 422

Health state effect, 422, 424

Health state preference, 422, 424

Health Systems and Policy Monitor, 474

Health technology assessment, 468

Health Utilities Index, 429

Healthy years equivalents, 429, 430

HEDIS. See Healthcare Effectiveness Data and Information Set

Heidenreich, P. A., 261

Hellinger, F. J., 248

“Help-seeking” advertisements, 256

Henderson, J. M., 47

Herfindahl-Hirschman Index, 210–11, 217

Hester, James, 102

Heuristics, 76, 77

HHI. See Herfindahl-Hirschman Index

Hibbard, Judith: consumer information, 69; cost sharing, 117; report cards, 71
Hierarchies of evidence: for economic evaluations, 441
High-deductible health plans, 404–5
Hill-Burton Act, 162
Hinshaw, S. P., 267
HIQRP. See Hospital Inpatient Quality Reporting Program
HIV/AIDS, 78, 382
HMOs. See Health maintenance organizations
Ho, J., 485
Hoerger, T. J., 67
Holland. See Netherlands
Home care, 252; for-profit ownership and, 232, 233
Hooker, R., 328
Horizontal equity, 357, 494
Horizontal integration, 207, 209, 210, 212, 269
Horizontal Merger Guidelines, 211
Horwitz, J. R., 247
Hospice care: for-profit ownership and, 232, 233
Hospital Compare, 72, 74
Hospital Inpatient Quality Reporting Program, 196
Hospitals: choice of, 464–65; competition, 208, 225; conversions, 273–74; cost–benefit analyses in, 414; cost shifting, 221–23; diagnosis-related group system and, 193, 194, 381, 399; economies of scale, 207, 226–27, 229n18; global budgets for, 410, 470–71; horizontal integration and, 209, 210; market power, 206, 209–12, 215–16, 307, 465; nonprofit, 221; ownership, 232, 232–33, 465; per diem payments, 193, 470; physician affiliations, 211–12; price discrimination, 220; as profit maximizers, 220–21, 221; quality in, 238–39; rate comparisons, 398; report cards, 73, 74; return to scale in, 226; selective contracting and, 215; vacancy rates, 313; vertical integration, 209, 210
Hospital Value-Based Purchasing Program, 196
Hough, D. E., 81, 123
Hours-adjusted internal rate of return, 341n13
Howard, D. H., 71
Howard, L. Z., 67
HRAs. See Health reimbursement arrangements
HSAs. See Health savings accounts
Hsieh, H., 243
Hsuan, C., 132
HTA. See Health technology assessment
Huberman, W., 173
HUI. See Health Utilities Index
Humana, 241
Human capital: development, 300, 303–4; theory, 84–85, 303
Human organ sales, 63, 64
Hurley, Jeremiah, 188, 189, 192
Hussey, P. S., 395
HVBPP. See Hospital Value-Based Purchasing Program
HYEs. See Healthy years equivalents
ICER. See Incremental cost-effectiveness ratio
Ikegami, N., 456, 473
Ill health: healthcare expenditures and, 400–401
Illich, Ivan, 266
IMGs. See International medical graduates
Immunizations: positive externality of consumption, 141, 142
Imperfectly competitive markets, 205–6, 212, 214
Imperfect substitutes: labor–capital decision in the long run, 294, 295
Improvement-based targets: pay-for-performance programs, 196
Incentive-based payment systems, 473
Incentive reimbursement, 120
Income: consumer-driven health plan products and, 133–34; demand and, 17; health outcomes and, 157–58; health status relationship, 154–55, 155; labor–leisure tradeoff and, 300–302, 301; physicians, 318, 319; social welfare and, 8
Income distribution: changing, taxation and, 159–61
Income effect, 18, 19, 189, 302
Income elasticity of demand: definition of, 21
Income inequality, 346–47; health and social problems relationship, 156–57, 157
Income taxes, 160
Increasing marginal productivity, 22, 22
Incremental cost-effectiveness ratio, 418, 441, 442, 449; analysis, steps in, 443–44; calculating, 419; of cost–utility analysis, 444, 445; of four treatment options to reduce ventilator-associated pneumonia, 442–43
Incremental utilitarianism, 348
Indemnity plans: HMOs compared with, 203
Independent practice associations, 211
India: happiness in United States vs. in, 148–50
Indifference curve, 9–11, 40; characteristics, 9; consumer, 10, 10, 18, 19; demand-for-leisure model, 301, 301; movement along, 20; Rawls’s Theory, 350; revealed preference theory, 59–60; utility, 9
Indirect costs, 426, 427
Individual mandate: Affordable Care Act and, 373
Industrial Revolution, 347
Inelastic demand for labor, 298
Inelastic goods and services, 20
Inequality: health and, 154
Inequitable tiered healthcare system: narrow networks and, 205
Infant mortality, 483, 484; income distribution and, 155
Inferior goods, 17, 18, 44n3
Information: access to, 62; asymmetries, 182, 190, 211, 236; comprehension, 68; costs, 64; health services system and, 498; overload, 76; use of, 65
Information Overload Research Group, 136n9
Inglehart, R., 147
Injustice, 349
Innovative ideas, 505
Institute of Medicine, 377; practice guidelines defined by, 195
Insurance industry: consolidation of, 211; market power and, 217–18
Intangible costs, 426, 427
Interdependent utilities, 10
Interest: compounded, 434
Intermediate measures, 428
Internal validity, 101
International Federation of Health Plans, 391
International medical graduates, 311, 312, 318, 328
International nursing graduates, 323
“International Profiles of Health Care Systems, 2013” (Commonwealth Fund), 474
Internet: report card information, 70
Inverse care law, 330
Investigational New Drug Application, 253–54
IOM. See Institute of Medicine
Ireland: diagnosis-related group adoption in, 470
Isocost line, 24, 25, 25, 295, 295, 296
Isoquants, 22, 23, 25, 45n6, 294
Italy: healthcare expenditures, 482; World Health Organization assessment, 474
“It’s the Prices, Stupid: Why the United States Is So Different from Other Countries” (Anderson), 390
Iyengar, S. S., 173

Japan: adult obesity rates, 488; all-payer system, 385, 406, 456; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; healthcare expenditures, 456, 480, 481, 482; health expenditures as share of gross domestic product, in 2011, 387; increasing healthcare expenditures in, 387; life expectancy and infant mortality, 483, 484; mammography screening and breast cancer survival, 486; medical technology use, 456, 467, 468; obesity rates, 487; per capita health expenditures, 2011, 386, 386; physician fee schedule, 473; postwar, happiness levels study, 146; provider choice in, 464; public programs, 476; public share of expenditures on medical services, 2011, 387, 387; smoking rates, 488; utilization rates, 479, 480; World Health Organization assessment, 474

Jeffers, J. R., 309
Jensen, R. T., 44n3
Jewett, Jacquelyn, 69
Jiang, H. J., 246
Jiang, W., 173
Jobs. See also Labor; heterogeneity of, 306; mobility, 306
Judge, K., 156
Justice, 344, 345, 347, 378; health in conception of, 360; Nozick’s conceptions of, objections to, 354
Kahneman, Daniel, 76, 78, 81, 167
Kaiser Permanente, 133, 207
Kaplan, B., 71
Kawachi, I., 155, 156
Kee, J. E., 439
Keeler, E., 247
Kefauver-Harris Amendments: to Food, Drug, and Cosmetic Act, 253
Kennedy, B. P., 155
Kessel, R., 39
Kessler, Daniel, 215
Kolko, Gabriel, 54n5
Kolstad, J. T., 70
Kondo, N., 156
Kronick, R., 89
Kuttner, Robert: commercialization, 271; market efficiency, 3; second-best considerations, 54n2

La Barbera, C. P., 256
Labelle, Roberta, 188, 189, 191, 192
Labor. See also Demand for labor; Supply of labor; complementary, 297; definition of, 291–92; demand function and curve: deriving, 297–98; demands, 291–300; elasticity of demand, 298–300; factors affecting demand, 316–18
Labor–labor substitution, 296; economic model for, 297; healthcare workforce and, 296
Labor–leisure model, 301, 301
Labor–leisure trade-off, 300–302, 301, 304
Labor market, 291; characteristics, 305–7; contractual relationships, 306; differences in, 307; economics of, 290–310, 339–40; equilibrium, shortages, and surpluses, 305; market power, 306; perfectly competitive, 305–6; supply and demand in, 302; unique characteristics of, 305–7
Labor supply: elasticity of, 304–5; factors affecting, 317–25; function and curves, deriving, 304; human capital development, 303–4; workforce, 300–303
Latinos: underrepresentation in health professions, 314
Laugesen, M. J., 391
Lawrence, W., 227
Lawsuits, 400
Leapfrog Group, 74
Le Grand, J., 54n4
Leibenstein, Harvey, 81
Lepper, M. R., 173
Lesser, D., 200
Lettau, M., 91
Lever, J., 80
Leveson, Irving, 102
Lexchin, J., 259, 263, 264
Li, Ling, 226
Liability costs, 321
Libertarian approach, 63
Libertarian paternalism, 172
Libertarian rights, 356
Libertarian theory (Nozick), 353–54
Licensed practical nurses, 296, 297, 332
Life expectancy, 377, 483, 484, 487; income distribution and, 155; medical technologies and, 395; weighted, 429
Light, Donald, 258, 259, 264, 491
Lindley, J., 156
Liptor, 262
Lithotriptors, 501n5
Lleras-Muney, A., 85–86
Loading costs, 87, 136n10, 173
Logic of Collective Action (Olson), 54n5
Lohr, K. N.: cost sharing, 100, 117; medical effectiveness grouping, 115, 116, 118
Lomas, J., 466
Long-run average costs, 28, 29
Long-run costs: economies of scale and, 27–30
Long-run equilibrium, 35, 35–36
Long-run period, 23
Lorgelly, P. K., 156
Loss aversion, 78–79, 90
LPNs. See Licensed practical nurses
LRAC. See Long-run average costs
Luft, H. S., 408
Lump-sum taxes, 159, 161
Lynk, W. J., 226, 227
Mackie, T., 267
Magnetic resonance imaging, 252, 467, 468, 501n5
Magnet Recognition Program, 338
Major depressive disorder: cost–utility of collaborative care for, 419, 420
“Make-or-buy” decision, 490
Malpractice claims, 321
Malpractice crises: physician dissatisfaction and, 322
Managed care: backlash and concerns about, 177n15, 201–4; concentration effects, 216; consumer backlash against, 177n15; cost containment, 120, 201, 408; hospital referrals, 464; market penetration by, 204; mechanisms, reemergence of, 204–5; Medicare plans, 91, 174; penetration, 218; physician dissatisfaction and, 322; price negotiation and, 393; quality issues, 201–4; selective contracting and, 215; shared savings and, 199; transformation of, 199; utilization management and, 198–99; volume controls, 471–72
Managed care organizations, 198, 201, 203
Managed competition: advantages of, 462; concerns, 460, 462; cost containment and, 403, 405; open enrollment requirement, 460; testing, 460
Marginal costs, 27; explanation, 27; short-run relationship, 28, 29, 30; welfare loss, 113, 114
Marginal product, 23
Marginal product of labor (MP_L), 292, 293
Marginal rate of substitution, 11, 40, 41, 43n1, 160
Marginal rate of technical substitution, 22
Marginal rate of transformation, 39, 40, 41, 160
Marginal revenue: calculation, 36–37, 37; curve, 212–13; definition, 36; imperfectly competitive markets, 212–13
Marginal revenue product of labor (MRPL), 292, 293
Marginal utility, 8, 13, 15–16; consumption externalities, 141; welfare loss, 114, 114
Margolis, Howard, 367, 368
Market: alternative relationships between government and, 452; government vs., 52–53
Market competition, 344, 503; regulation of, 208
Market failures, 47, 49
Market power, 36, 340; accountable care organizations, 212; achieving, 207; consolidations and, 213–14; cost shifting and, 220; definition of, 205; demand for healthcare labor and, 316; health policy implications, 218–19; hospital, 206, 215–16, 307, 465; in insurance market, 211, 217–18; issues with, 212–15; labor market, 306; lack of, among purchasers of services, 391, 393–94; physician, 211; trends in, 209, 209–12, 210; of US providers, 390–91
Market reliance in health: intellectual case for, 4
Markov cycle tree: simple, 438
Markov decision models, 435, 437, 438
Markov node, 438
Marmot, Michael, 153
Marshall, Alfred, 109, 169
Martin, P., 266, 267
Mass QC, 74
Matsuoka, K. Y, 108
Maximin principle: in Rawls’s Theory, 349, 351
Maynard, Alan, 451, 493
McClellan, Mark, 215, 261, 395
McCormack, L. A., 73
McGuire, Thomas, 117, 122, 124, 189, 402
McKay, N. L., 246
McKee, C. M., 483
McKie, J., 355, 361, 362
MCOs. See Managed care organizations
McPherson, Michael, 345
MDD. See Major depressive disorder
Mechanic, David, 66, 123
Medicaid, 161, 162, 194, 219, 252, 334, 404, 454; administration of, 458; Affordable Care Act and, 374, 375; aggregate hospital payment-to-cost ratios for, 222–23, 223; cost-sharing exemptions, 494; cost-shifting studies, 224; coverage, 371; expansions in eligibility, 384; managed care component, 408; nonprofit health plans and, 245; Oregon study, 104–6; physician adequacy, 327; physician restricted access and, 321; rationing of services, 163–64; unit price determinations, 393
Medical imaging: sharp downturn in utilization, 394
Medicalization, 256, 266, 267, 269, 401
Medically underserved communities, 330
Medical malpractice: healthcare expenditures and, 400
Medical profession: entering, factors related to, 318–19
Medical savings accounts, 128
Medical school graduates: debt level of, 318
Medical technology: cross-country comparison, in 2009, 468; proliferation of, healthcare expenditures and, 394–96; use controls, 467–69, 491, 504
Medicare, 162, 219, 252, 334, 414, 454, 469; access-to-care issues, 330; accountable care organizations and, 199; administration of, 458; Affordable Care Act and, 374; Affordable Care Act, primary care fee schedules, and, 337; aggregate hospital payment-to-cost ratios for, 222–23, 223; allocation and, 161; beneficiary price sensitivity, 91; cost-shifting studies, 223–24; diagnosis-related groups and, 194, 470; drug plans, 3, 174–75; fee-for-service component, 406; fee schedule, 466; Hospital Compare, 72, 74; hospital spending, 381; managed care component, 408; managed care plans, 91; managed competition and, 405; medical imaging reimbursement policy, 394; movement away from fee-for-service, 497; Part D, 162, 272; payment rates and demand, 187, 188; physician fee schedule, 471–72; physician restricted access and, 321; prescription drug coverage, 384, 496; price discrimination, 220; primary care shortage, 312; prospective payment system, 122; regional variation in medical services, 398–99; relative values, 501n7; specialist ratios and expenditures, 332; specialty hospitals and, 250; unit price determinations, 393; upcoding of claims, 242
Medicare Advantage, 92, 162, 404
Medicare and You, 73
Medicare Payment Advisory Commission, 336–37
Medicare Provider Analysis and Review files, 247
Mehrotra, A., 267
Mello, M. M., 321
Mellor, J. M., 156
Melnick, G., 217, 247
Mencken, H. L., 144
Mendoza, R., 315
Mergers, 207, 208, 209, 213, 215–16
Me-too drugs, 261, 262, 264
Milgram, Stanley, 167–68, 178n19
Mill, John Stuart, 144
Miller, D., 352
Miller, N. H., 44n3
Miller, R. H., 408
Miletstein, A., 132
Milyo, J., 156
Minimalist state, 353
Minorities: underrepresentation in health professions, 314–15
Mishan, E. J., 47
Monopolistically competitive markets, 206
Monopolistic market: disadvantages for society, 38
Monopolists: pricing and output decisions by, 213, 214
Monopoly, 206, 218, 226, 393; classifications, 36; economies of scale, 207; equilibrium in, 36–39; marginal revenue curve, 212–13; natural, 38; power, 36, 217, 261–62, 264; price-discriminating, 38–39, 219–20; single-price, 36–38, 38
Monopsonistic power, 217, 218, 317, 334, 340, 393, 403, 406, 495
Monopsonists, 206–7
Monopsony, 36, 218, 306, 307
Monte Carlo simulations, 438–39
Mooney, Gavin, 191, 357, 366, 376
Moral hazard: RAND experiment, 93–94, 93–104; welfare loss argument, 95–97, 110, 111, 112
Morgenstern, Oskar, 228n10
Morone, James, 495
Morrison, K. R., 97
Mortality: hospital ownership and, 239
Morton, F. S., 210, 211
MRI. See Magnetic resonance imaging
MSAs. See Medical savings accounts
Mueller, Dennis, 52
Multiattribute scales, 429
Multi-level studies, 156
Murphy, K. M., 81
Music: market behaviors and taste for, 169
Nallamothu, B., 251
“Narrow networks,” 204
NAs. See Nursing assistants
Nash, John, 228n10
Nath, S. K., 47
National Committee for Quality Assurance, 69
National Guidelines Clearinghouse, 195
National Health Service Corps, 336, 337
National Health Service (United Kingdom), 407, 414, 451, 453, 455–56, 473
National Institute for Health and Clinical Excellence (United Kingdom), 407, 414, 469
National Institutes of Health, 498
National Science Foundation, 262
Natural monopoly, 38, 207
Need: demand vs., 308, 309, 310
NEED Act. See Nurse Education, Expansion, and Development Act
Needleman, J.: community benefits study, 243, 244; cost-effective staffing, 333; quality study, 241; upcoding, 242
Negative consumption externalities, 141, 142
Negative production externalities, 140–41, 176n1
Negotiating power: undue, US providers and, 393–94
NER. See Not economically rational
Net benefits: in cost–benefit analysis, 444–46
Netherlands: adult obesity rates, 488; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; compulsory purchase of private insurance in, 387; demand inducement, 190; funding sources, 455; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 119, 481, 481, 482; healthcare sector changes in, 451; healthcare system reform in, 3; health expenditures as share of gross domestic product, in 2011, 386, 387; hospital system, 465; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 485, 486; managed competition, 405, 460–62, 500; medical technology use, 468; per capita health expenditures, in 2011, 386; private insurance, 384; public programs, 476; public share of expenditures on medical services, in 2011, 388; service wait times, 479, 492; smoking rates, 488; specialist-to–primary care physician salary ratio in, 319; uninsurance rates in, 375; unit prices, 391, 392; user charges, 494; utilization rates, 479, 480; World Health Organization assessment, 474
Net present value analysis, 435
New drug application, 253–54
Newhouse, J. P., 330; nonprofit/for-profit comparisons, 236; RAND study, 101, 103
New Zealand: adult obesity rates, 488; amenable mortality, 485; average real expenditure growth,
2000–2009 vs. 2009–2011, 389; economic analyses, 469; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 480, 481; health expenditures as share of gross domestic product, in 2011, 387; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 486; medical technology use, 468; per capita health expenditures, in 2011, 386, 387; pharmaceutical advertising, 256; public programs, 476; public share of expenditures on medical services, in 2011, 388; service wait times, 476, 492; smoking rates, 487, 488; unit prices, 391, 392; user charges, 494; utilization rates, 479, 480

Nexium, 262
Ng, Y.-K., 47

NHS. See National Health Service
NICE. See National Institute for Health and Clinical Excellence

Nisbett, R. E., 167
No Child Left Behind, 267
Nolte, E., 483

“Noninferiority” requirement: new drug testing and, 261

Nonmedical responsibilities: physician dissatisfaction and, 322

Nonprofit organizations: altruistic goals, 236; community benefit, 274; community commitment and service, 243–45; costs, 236, 245–46; efficiency, 237, 245–46; financial performance, 247, 272; for-profit comparisons, 235–38; goals for, 235, 236, 237; legalities, 235; market power, 237, 247–48; market pressures, 235; organization, 235; prices, 247; quality, 274; quality reviews, 238–41; taxes, 235; trustworthy behavior, 236, 237, 241–42, 274; upcoding, 242

Nonprofit ownership: hospital care and, 232, 233

Normal goods, 17, 18

Norway: adult obesity rates, 488; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; diagnosis-related group adoption in, 470; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 480, 481, 482; health expenditures as share of gross domestic product, in 2011, 386, 387; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 486; per capita health expenditures, in 2011, 386, 387; public programs, 476; public share of expenditures on medical services, in 2011, 388; service wait times, 479, 492; smoking rates, 487, 488; user charges, 494; utilization rates, 479, 480

Not economically rational, 444

Nozick, Robert, 353, 354, 356

NPs. See Nurse practitioners

NPV analysis. See Net present value analysis

Nudge (Thaler and Sunstein), 81

Nurse anesthetists, 284

Nurse Education, Expansion, and Development Act, 337

Nurse Faculty Scholars Program, 338

Nurse midwives, 284

Nurse practitioners, 284, 286, 296, 312, 326

Nurse practitioner services: short-run equilibrium, 33, 34

Nurse practitioner visits: budget constraint, 11–12, 12; consumer indifference curve, 10, 11; consumer optimum, 13–14, 14; consumer...
Nurse practitioner visits (continued) surplus, 109–10; demand curves, 15, 15, 16; Edgeworth box, 39–40, 41; income and substitution effects, 18, 19, 20; long-run equilibrium, 35, 35–36; producer optimum and, 25, 26; production possibility frontier and, 39–40, 40; total product curves, isoquants, and, 22–24

Nursing: entering field of, 323
Nursing assistants, 287, 296, 297, 328, 341n5
Nursing education faculty: registered nurse shortages, 314
Nursing homes: efficiency and cost-effectiveness of, 246; for-profit ownership and, 233; market power, 211; pay for performance, 195; profit maximization strategies, 242; quality of care in, 239–40, 332
Nussbaum, M. C., 170, 358, 359, 360
Nyman, John, 103, 104; on RAND findings, 114; welfare gains, 112, 115, 118–19

Obama, Barack, 3, 373
Obedience: Milgram experiment, 167–68
Oberlander, J., 164
Obesity: annual economic costs of, in United States, 401; epidemic, 171; rates, 487, 488
Occupational choices: factors related to, 300; market behaviors and, 170
Occupational Outlook Handbook (Bureau of Labor Statistics), 341n3
OECD countries. See Organisation for Economic Co-operation and Development countries
Office of Technology Assessment, 468
Ohri, S., 91
Oligopoly, 36, 206, 218
Oligopsonists, 206
Olson, Mancur, 54n5
Omitted variables bias, 186
Ontario Medical Association, 393
Open enrollment, 460
Open-heart surgical procedures: economies of scale, 226, 229n17
Opportunism, 491
Opportunity, equalizing, 359
Opportunity costs, 32, 160, 281n6, 381, 434
Opt-outs: organ donation and, 77; savings accounts and, 83
Ordinal utilitarianism, 345; cash transfers, 369; dispute with, 348; equalization under, 358; issues with, 347–64; Rawls’s theory, 349–53; social justice/fairness, 348–49; social welfare, 347, 357–58
Oregon: rationing of Medicaid services in, 163–64
Oregon Experiment: patient cost sharing and, 404
Oregon Health Insurance Experiment, 60, 104–6, 117
Organ donation, 172
Organisation for Economic Co-operation and Development countries, 319, 387, 418, 499; average real expenditure growth by type of service, 2008–2011, 390; healthcare spending, 119
Orthopedic surgeons: incomes across six countries, 391
Osteopathic physicians: growth in, 312
Other value created, 422, 424
Out-of-pocket maximum, 68
Outpatient surgeries, 252
Overdo$ed America: The Broken Promise of American Medicine (Abramson), 271
Overhead costs, 426
Overtime work, 302
Owings, M., 184
Index

Paradox of Choice: Why More Is Less (Schwartz), 172
Parente, S. T., 132
Pareto, Vilfredo, 41
Pareto optimality, 61, 83, 151, 160, 503; equity, social welfare, and, 41–43
Pareto principle, 9
Parliamentary-style governments, 488
Partial equilibrium analysis, 39
Participation altruism, 368
Participation in workforce: supply of labor and, 300–303
PAs. See Physician assistants
Patents: new drug development and sales, 254
Paternalism, 63–64
Patient-centered care, 192, 197–98
Patient-centered medical homes, 192, 197–98, 200, 203, 335
Patient-Centered Outcomes Research Institute, 407, 414, 469, 498
Patient Protection and Affordable Care Act of 2010. See Affordable Care Act
Pauly, Mark, 60, 189; consumer information, 66; government failure, 49; moral hazard, 94; nonprofit organization goals, 236; welfare loss argument, 110–11, 111
Paxil, 259, 269
Pay for performance, 120, 194–95, 196, 200, 202–3, 322, 409, 410, 473
PCMHs. See Patient-centered medical homes
PCORI. See Patient-Centered Outcomes Research Institute
PCPs. See Primary care physicians
Peacock, A. T., 47
Peltzman, Sam, 51
Per capita demand: reducing, 334
Per diem payments, 193
Perfect agents: for patients, physician potential as, 182–83
Perfectly competitive markets, 212
Perfect substitutes: labor–capital decision in the long run, 294, 295
Performance “attainment”: rewarding, 410
Performance “improvement”: rewarding, 410
Persad, G., 357, 363
Peterson, L. E., 328
P4P. See Pay for performance
Pharmaceutical Benefits Advisory Committee (Australia), 469
Pharmaceutical industry: political influence of, 278–79
Pharmaceuticalization, 266–67, 269
Pharmaceutical Research and Manufacturers of America, 254
Pharmaceuticals, 252–65. See also Prescription drugs; clinical trials, 253; conflict of interest, 276; “disease mongering,” 258; direct-to-consumer advertising, 255–57, 263, 269, 276; effectiveness of, 257–58, 260–62; guidelines and, 258; marketing of, 255–58, 277; monopoly power, 261–62, 264; negative growth for, 388; new drug development, 253–54; patents, 254, 264, 278, 279; policies, 276–79; price controls, 277–78; research and development costs, 254–55,
Index

Pharmaceuticals (continued)  
262, 263–64, 278; regulation, development, testing, and costs of, 253–55, 277, 279; safety of, 259–60, 276; spending on, 262–64, 263; summary of, as example of commercial healthcare sectors, 265; surrogate endpoints, 257–58, 261; unit prices, across seven countries, in 2013, 391, 392

Phillips, J., 236, 319
Phillips, R. L., 328
PhRMA. See Pharmaceutical Research and Manufacturers of America

Physical therapists, 286

Physician assistants, 284, 286, 296, 312, 328

Physician ownership: decline in, 233

Physician-to-population ratios: demand inducement test, 184–87; increasing, 311

Physicians: access to care, 330; active, in primary care, 1949–2011, 289–90, 290; annual salary, 193; compensation by specialty, 2013, 288; cost shifting and, 224; debt-to-income ratios, 318, 319; demand inducements, 182, 183–84, 191–92, 197; dissatisfaction among, 321–23; educational period for, 284; employed per 100,000 population, 1980–2012, 289, 289; financial risk sharing and, 200; forecasting models, 325, 326; generalists, 284; hospital affiliation, 211–12; improving distribution of, 336–37; incomes, 287, 318, 319; information asymmetries and, 182, 190, 211; location choice, 186, 308, 320; market power, 189, 211; optimizing supply of, 335, 337, 340; as patient agents, 182, 197; pay for performance, 194–95; payment, 187–90, 193, 408, 409, 456, 466–67, 471–73; pharmaceutical company marketing and, 257; practice choice, 319–20; professional autonomy, 322; retiring, 322–23; specialists, 284; supply, 179, 289, 289, 308, 310, 311–13, 326, 327, 330, 334, 466–67; training, 162; workforce adequacy forecasts, 327–28, 340; workloads, 321

Physician services: income and substitution effects, 18, 19, 20

Physician specialty societies, 407

Physician-to-population ratios: population health and, 331; variation in, 313

Physician visits: budget constraint, 11–12, 12; consumer indiffERENCE curve, 10, 11; consumer optimum, 13–14, 14; demand curves, 15, 15, 16; Edgeworth box, 39–40, 41; production possibility frontier and, 39–40, 40

Pickett, K. E., 156
Pigou, A. C., 144, 371
Piketty, Thomas, 347
Placebo, 261, 262

Point-of-service plans: gatekeeper and, 199

Political science, 165

Poll tax, 160

Population ill health: healthcare expenditures and, 400–401

Portugal: diagnosis-related group adoption in, 470

Positive consumption externalities, 158, 370

Positive production externalities, 140, 141

Positron emission tomography (PET) scans, 252

POS plans. See Point-of-service plans

Possibility theorem, 43

Poverty rate levels: US, 136n11

PPF. See Production possibility frontier
PPOs. See Preferred provider organizations

Practice guidelines, 192, 195, 200, 203, 399, 407–8, 504

Practice-makes-perfect hypothesis, 227

Precertification, 197

Preferences, 150, 176n4, 178n18, 178n25, 367–68; formation of, in traditional model, 165–66; redistributing resources and, 159

Preferred provider organizations, 199, 408; consumer preference, 201; deductibles, 135; out-of-pocket costs, 131; patient cost sharing and, 404; physician payment, 408; utilization management, 198

Preker, A. S., 491

Premier Inc. demonstration project, 202

Premiums: Affordable Care Act and, 373; competitive level of, 129–30; managed competition and, 405; narrow networks and, 204–5; risk-adjusting, 460

Prescription drugs. See also Pharmaceuticals; Medicare coverage, 174–75; patient cost sharing and, 404; spending on, 26, 262–64; value-based insurance design, 127

Present bias, 77–78

Present value, 434; calculation, formula for, 434–35; definition of, 434; future costs added for, 435

Present value analysis, 303–4, 434

Presidential system, 488

Preston, S. H., 485

Prevention: expenditures and focus on disease vs., 401

Preventive services, 108, 117, 125, 133, 138n24, 204, 330, 334–35; curative services vs., 401; negative growth for, 388

Price: demand and, 17–18; demand for health insurance and, 91–92; discriminators, 229n14

Price competition: imperfectly competitive markets and, 206

Price-discriminating monopolist, 38–39, 219–20

Price elasticity of demand, 20, 33, 91, 124–28, 220; calculation, 44–45n4

Price elasticity of medical spending: RAND Health Insurance Experiment and, 125, 126

Price elasticity of supply, 33

Price transparency, 402–4, 403

Prilosec, 262

Primary care: medical education “hidden curriculum” and, 319

Primary Care Health Professional Shortage Areas, 313

Primary care panels: downsizing of, 328

Primary care physicians, 200, 296; access to care, 330; competitive relationships, 286; cost control and, 395–96; future adequacy of, 328; healthcare expenditures and, 332–33; improving distribution of, 336–37; incomes across six countries, 391; patient-centered medical home model, 197–98; population health and, 331–32; shortage areas, 312, 313; supply, 290

Primary care–specialty payment gap, 319

Primary goods: definition of, 349; equal distributions of, 350, 358

Prime lending rate, 434

Prioritarianism, 363–64

Private insurance: administration costs, 396–98; international comparisons, 384; marketing costs, 396; profit maximization and, 220, 221; role of, 458–62

Private market: contestability of, 490

Private nonprofit organizations: for-profit growth and conversions of, 234

Private–public sector intersection, 452
Private sector rate of return, 434
Proactive conversions, 234
Producer optimum, 25, 26
Production costs, 26–30
Production externalities, 139–40
Production function, 21–22
Production possibility frontier, 39, 40, 43
Production process model: demand for labor in the short run, 291–92
Productivity, improving, 371–72
Productivity principle, 356
Profit maximization, 25, 30, 39, 220–21, 231, 242
Profit motive: assumptions tied to, 231; in traditional economic theory, 231
Progressive consumption tax, 151–52, 176–77n6
Property rights theory, 141, 236
Prospective fixed payment systems, 193
Prospective payment systems: hospital staffing levels, 317; supply-side cost sharing and, 122
Prospective reimbursement, 215
Prothrow-Stith, D., 155
Provider: choice of, 464–65; coordinated payments, 456
Provider payment policies: cost containment and, 403, 408–10
Prozac, 269
Prudential: merger with Aetna, 217
Public choice theory, 51–52
Public goods theory, 237
Public health: negative growth for, 388
Public Health Act: Title VII of, 320
Public interest theory, 50, 51
Publicly mandated systems: benefits in, 462–63
Public nonprofit organizations: for-profit growth and conversions of, 234
Public–private sector intersection, 452
Public programs, 460, 475
Public redistribution programs, justification for, 370
QALYs. See Quality-adjusted life years
QoL measures. See Quality-of-life measures
Quality: in dialysis units, 240–41; in health plans, 241; in hospitals, 238–39; in nursing homes, 239–40
Quality-adjusted life years, 361, 407, 419; cost–utility analyses and, 444; coverage thresholds, 469; disability-adjusted life years vs., 432; expressing, 429
Quality of care: nurse staffing levels and, 332; physician supply and, 330–32
Quality-of-life measures, 419, 428–30, 449; cost–utility analyses and use of, 429; preference scores used in, 429
Quality of Well-Being scale, 429
Quandt, R. E., 47
QWB scale. See Quality of Well-Being scale
Race: physician choice of geographic location and, 320
Radiation therapy, 501n5
Radical utilitarians, 8
Rakowski, W., 108
RAND Health Insurance Experiment, 60, 93–104; application to policy, 137n14; arc price elasticities of medical spending in, 126; coinsurance conclusion, 117; critique of, 101–4; description of, 94–97; health status findings, 99–100; medical effectiveness groupings, 115, 116, 118, 129; patient cost sharing, 122, 128, 404; price elasticities of medical spending, 125, 126; utilization findings, 97, 97–99; validity issues, 101–2; welfare loss estimates, 95, 112
Rank-based targets: pay-for-performance programs, 196
Rate of return, 303
Rational, 80
Rational addiction theory, 81
Rational choice theory, 51–52
Rational consumer, 13, 90–91
Rationality: definition of, 80, 81
Rationalization, 81
Rationing of healthcare services, 366
Rawls, John, 146, 148, 159, 349, 352, 353, 354, 355, 356
Rawls’s theory: as alternative to utilitarian philosophy, 349; critique of, 351–53; “difference principle,” 349; indifference curves, 350; libertarian critique, 353–54; “maximin” in, 349, 351; reallocation, 353; representative person in, 352; social welfare under, 350
Reactive conversions, 234
Reber, S. J., 130, 131
Recession of 2008: negative expenditure growth and, 388; registered nurse graduates and, 313, 329
Reciprocity, 364, 364
Redisch, M., 236
 Redistribution of income: reasons for, 158–59
 Redistribution of wealth: equity and, 41
Reed, M. E., 133
Referrals, 197, 464
Regionalization, 226
Registered nurse faculty: increasing number of, 337–38
Registered nurse–to-patient ratios: cost-effectiveness and, 333
Registered nurse–to-population ratios: shortage areas, 314
Registered nurses, 297; chronic shortages, 283; cost-effective staffing, 296, 333; demand for, 317; dissatisfaction factors, 324, 339, 342n18; educator shortage, 329; employed per 100,000 population, 1980–2012, 289, 289; forecasting models, 325, 326; immigration/emigration, 323, 329, 337, 339, 342n18; payment, 408–9; practice setting choices, 323–24; recruitment/retention, 337–39, 340; reducing job turnover, 333; staffing levels and quality of care, 332; supply, 287, 307, 310, 313–14, 317, 324, 326, 329; wages, 317, 323, 324–25; workforce adequacy forecasts, 329; working conditions, 286, 338–39, 340; workloads, 317
Regulators: equilibrium, 54–55n6
Regulatory agencies, 51
Regulatory capture, 488, 489
Reimbursement incentives, 192–93, 198
Reimbursement mechanisms, 215
Reinhardt, Uwe, 112; all-payer system, 495; consumer information, 65–66, 67; demand inducement, 191–92; envy, 151; inefficiency, 161; physician-to-population ratios, 184; relative status, 143; status seeking, 151
Relative deprivation, 145–52
Relative income hypothesis, 145
Relative values, 471, 501n7
Reminder advertising, 256
Report cards: comprehension, 69, 73; counterfactual issues, 74–76; disadvantages, 73–74; format, 71, 72, 72; impact of, 70, 71–72; Medicare information, 73; quality improvement, 71; quality measures, 69; use of, 69; vulnerable populations and, 70
Representative person, in Rawls’s theory, 352
Research funding, 497–99
Resources: capabilities and allocation of, 361–64; equalization of, 357; redistribution of, 158–59
Resources saved method, 432–33
Retrospective reimbursement, 215
Return on investment, 303–3, 318
Revealed preference, 59–60, 81
“Reverse Robin Hood” effect, 134
Rice, Nigel: capitation, 497; physician-to-population ratios, 184
Rice, T., 97, 108, 191, 393
Richardson, J., 355, 361, 362
Risk adjusting premiums, 460
Risk adjustment of payments, 138n27
Risk aversion, 86–87, 88
Risk selection, 193
Ritalin, 268
RNs. See Registered nurses
Robbins, Lionel, 143
Robert Wood Johnson Foundation: career development award, 338
Robinson, J. C., 217, 224
Robinson, James, 409
Robinson, Joan, 5, 176n4
Rodgers, G. B., 155
Rodwin, Marc, 73, 74
Roemer, John, 170, 359
Roemer’s law, 465
ROI. See Return on investment
Rosenthal, M. B., 132, 330
Rosiglitazone (Avandia), 258
Ross, L., 167
Rothberg, M. B., 74
Rowley, C. K., 47
Rule of rescue, 361–62, 379n17
Rural communities: physician location choices and, 320
SAD. See Social anxiety disorder
Sagoff, Mark, 367
Salaries: physician, 193; specialists and, 466
Sales taxes, 160
Saloner, B., 377
Saltman, R. B., 464
Samuelson, Paul, 59, 160–61
Sanmartin, C., 466
Sargen, M., 328
Sarkis, Elias, 268
Saturation point, 9
Savage, L. J., 87
Schachter, D., 225
Scheffler, R. M., 267
Schlesinger, M., 69, 239, 240, 243
Schneider, E. C., 395
Schoenbaum, Stephen, 484
Schut, Frederik, 461
Schwartz, Barry, 172, 173
Schwarzenegger, Arnold, 172
Scitovsky, Tibor, 64, 150
Selection bias, 129, 460
Selection effects, 133
Selective contracting of physicians, 192, 197, 202, 215, 408
Selective serotonin reuptake inhibitors, 258
Self-dealing, 234
Self-employed health insurance, 91
Self-employed professionals, 307
Self-insuring, 90
Self-justification, 81
Self-referrals, 208, 251, 275
Sen, Amartya, 47; allocation formula, 355; competitive equilibrium, 42; equality, 356, 359, 360, 361; healthcare, 377; sympathy vs. commitment, 368; welfarism, 83
Sensitivity analysis, 437–39, 446, 449
Sequist, T., 320
Sethi-Iyengar, S. G., 173
SGR. See Sustainable growth rate
Shen, Y. C., 247
Shifting supply curves, 46n7
Shortage, 33, 305
Short Form 6D, 439
Short run: production costs in, 26–27
Short-run average costs, 28, 28, 29, 29
Short-run equilibrium, 33–34, 34
Short-run period, 23
Sickness fund, 393, 454, 455, 456, 457, 460, 461, 500, 500n1, 501n3
Sidgwick, Henry, 49
Simon, C. J., 218, 241
Simon, Herbert: bounded rationality, 76
Single-payer system, 393, 406, 410, 455
Single-price monopolists, 36–38, 38
Siu, A. L., 117
Sloan, Frank, 66, 203, 247
Smith, Peter, 497
Smoking: annual economic costs of, in United States, 401; government-sponsored health education and, 171; as negative consumption externality, 141, 142; rates, 487, 488
Social anxiety disorder, 258, 269
Social choice, 348
Social envy, 165
Social insurance, 82–83; in Europe, 384
Social justice, 148, 159, 348; universal coverage in name of, 372, 376–77
Social psychology, 165
Social rate of time preference, 434
Social Security, 82
Social standing, 153
Social Transformation of American Medicine (Starr), 266
Social usefulness: promoting and rewarding, 364
Social welfare, 165; Bismarck style, 455; conceptions of, 355–56; consumer choice and, 61–62, 168; function, 43, 348, 358; income and, 8; maximizing, 346; Pareto optimality, equity, and, 41–43; under Rawls’s theory, 350; social justice and fairness, 348–53; universal healthcare coverage and, 376; utilitarian conception of, 347–48; utility maximization and, 83–84
Sociology, 165
Solidarity, 460
South Africa: happiness levels study, 146–47
Sozialgesetzbuch, universal coverage in Germany and, 453
Spain: healthcare expenditures, 482
Special interest groups, 50, 51, 52, 163, 489
Specialist care: population health and, 331, 332; reducing use of, 197
Specialization: proliferation of, healthcare expenditures and, 395–96
Specialty hospitals, 252; competition from, 249–50, 251; definition of, 248–49; diagnosis-related groups and, 250, 251; growth in, 249; issues with, 248–51; patient satisfaction in, 249; physician self-referrals and, 251, 275; policies, 275–76
Specialty practices, 319
Spurling, G., 257
SSRIs. See Selective serotonin reuptake inhibitors
Stabile, M., 452
Stable preferences, 81
Staiger, D. O., 326, 329
Standard gamble method, 429, 430
Starfield, B., 331, 395
Stark law, 251, 276
State-based health insurance exchanges: Affordable Care Act and, 373
Status quo bias, 68, 77
Stickk.com, 79
Stigler, George, 50, 51, 166
Stoddart, G., 191
Stone, Deborah, 93, 112, 121, 357
Strattera, 259
Stress: primate studies, 153; social standing, 153
Subjective well-being, 147, 149
Subramanian, S. V., 156
Subsidies, 159, 160, 161, 162, 177, 204; Affordable Care Act and, 373, 374; health insurance premiums, 90
Substitutes: definition of, 16; elasticity and, 21; example of, 18; positive cross-price elasticities, 21
Substitution, 286; effect, 18, 19, 20, 44n3, 189, 302; marginal rate of, 11, 40, 41, 43n1, 160
Sugden, Robert, 59
Sunstein, C. R., 81, 172
Supplemental insurance, 501n4
Supply: aggregate, 31; definition of, 179; demand relationship, 181–205; elasticity of, 33; of healthcare labor, 309, 309; of healthcare workforce, 179; optimization policies, 335–37; price elasticity of, 33; short-run equilibrium, 33, 34, 34; utilization reduction mechanisms, 192–205
Supply controls: explicit, advantages/disadvantages of, 469
Supply curve, 15; backward-bending, 188, 188–89, 228n1; derivation of, 30–33; shifting, 46n7
Supply of labor: elasticity of, 304–5; human capital development, 303–4; participation in the workforce, 300–303
“Supply-Side and Demand-Side Cost Sharing in Health Care” (Ellis and McGuire), 402
Supply-side cost containment methods, 402, 491–93; global budgets, 403, 410; managed care, 403, 408; monopsonistic power, taking advantage of, 403, 406; provider payment policies, 403, 408–10; technology/supply controls and cost-effectiveness analysis, 403, 406–7; utilization management and practice guidelines, 403, 407–8
Supply-side policies: cost sharing, 122; healthcare services and, 120
Surgeon General of the United States, 401
Surplus, 33, 305
Surrogate endpoints, 257–58, 261
Surrogate measures, 428
Sustainable growth rate, 471, 472, 473
SWB. See Subjective well-being
Sweden: adult obesity rates, 488; amenable mortality, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; Beveridge-style system in, 455; decentralized system in, 385; decline in total hospital beds, 466; generalists and specialists as percentage of all doctors, in 2011, 396, 397; healthcare expenditures, 481, 482; health expenditures as share of gross domestic product, in 2011, 387; hospital system, 465; income inequality in, 347; life expectancy and infant mortality, 483, 484; mammography screening and breast cancer survival, 486; per capita health expenditures, in 2011, 386, 386; private health insurance, 459; public programs, 476; public share of expenditures on medical services, in 2011, 388; regional administration, 458; single-payer system in, 455; smoking rates, 487, 488; universal coverage in, 453–54; user charges, 494; utilization rates, 479, 480; World Health Organization assessment, 474
Switzerland: average real expenditure growth, 2000–2009 vs. 2009–2011, 389; cost-sharing requirements, 464; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 480, 481, 482; health expenditures as share of gross domestic product, in 2011, 386, 387; life expectancy and infant mortality, 484; managed
competition, 460; medical technology use, 468; per capita health expenditures, in 2011, 386, 386; private insurance in, 384; public programs, 476; public share of expenditures on medical services, in 2011, 388; service wait times, 476, 479, 492; unit prices, 391, 392; user charges, 493, 494; utilization rates, 480; World Health Organization assessment, 474

Sympathy: commitment vs., 368

Takeovers, 207

Tastes, individual, 17, 483

TAT. See Treatment adherence therapy

TAU. See Treatment as usual

Tax systems: publicly administered coverage and, 456

Taylor, D., 247

Team approach: to care delivery, 335

Tea Party (US), 52

Technical efficiency, 24

Technology, 164, 177n15, 292; controls, 120, 192, 200; cost containment and evaluation of, 403, 406–7

Terminal nodes: in decision trees, 435, 436; in Markov decision model, 438

Thaler, R. H., 81, 82, 172

Thalidomide birth defects, 253

Theory of demand for health insurance, 86–91

Theory of demand for health services, 93

Theory of Justice (Rawls), 159, 349, 355

Theory of the second best, 53–54n2

Thinking, Fast and Slow (Kahneman), 76

Thorpe, Kenneth, 171

Threshold targets: pay-for-performance programs, 196

Thurow, Lester: equity of access, 366; relative status, 144; restrictive assumptions, 4; revealed preferences, 81; social sciences, 165

Time preference, 85

Time pressures: physician dissatisfaction and, 322

Time trade-off method, 429, 430

Total costs, 26, 27, 27

Total product curve, 22, 22

Town, R. J., 218

Traditional economic model, 345–47; critique of, 60–84, 166–70; formation of preferences in, 165–66; problems with, 347–64

Traditional economic theory: price transparency and, 402

“Tragedy of the Commons” (Hardin), 140

Transformation, marginal rate of, 39–41, 160

Transition nodes: in Markov decision model, 438

Transitive, 80

Treatment adherence therapy, 416, 419

Treatment as usual, 417

Trivedi, A. N., 108

True experimental design, 101, 106

Trust: stratified society and lack of, 154

Trust signal theory, 236

Trustworthy behavior, 274; definition of, 242; for-profit/nonprofit comparison, 241–42

Tullock, Gordon, 351

Tuohy, C. H., 452

Tusler, M., 117

Tversky, Amos, 78

Tying arrangements, 208

UM. See Utilization management

Unbundling of services, 193

Uncompensated care costs, 225
Uninsured population, 131, 243, 475–76, 484; access-to-care issues, 330; Affordable Care Act and, 375; physician restricted access and, 321; private sector coverage and, 3; in United States, 454

Unions, 306

Unitary elastic goods and services, 20

Unitary elasticity, 298

United Kingdom: adult obesity rates, 488; amenable mortality, 484, 485; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; cost-sharing requirements, 464; decline in real spending in, 387; equity of health system financing, 499; generalists and specialists as percentage of all doctors, in 2011, 397; healthcare expenditures, 481, 482; healthcare sector changes in, 451; health expenditures as share of gross domestic product, in 2011, 387; hospital ownership, 465; hospital system, 465; income inequality, in, 347; life expectancy and infant mortality, 484; mammography screening and breast cancer survival, 485, 486; managed competition, 500; medical technology use, 468; nationalized system in, 385; patient cost sharing in, 404; per capita health expenditures, in 2011, 386, 386; physician fee schedule, 473; primary care trust, 457; public financing in, 384; public ownership of health resources, 490; public programs, 476; returns to scale in, 227; service wait times, 476, 492; smoking rates, 488; unit prices, 391, 392; universal coverage in, 453; utilization rates, 479, 480; World Health Organization assessment, 474

United States: access, 372; administrative costs in, 396, 397; adult obesity rates, 488; amenable mortality, 484, 485; attention-deficit hyperactivity disorder rate in, 267; average real expenditure growth, 2000–2009 vs. 2009–2011, 389; commercialized healthcare in, 269; consumer choice, 496; debate over high healthcare prices in, 393; decline in total hospital beds, 466; diagnosis-related group adoption in, 470; economic evaluation in, 414; extension of health insurance in, 3; generalists and specialists as percentage of all doctors, in 2011, 396, 397; happiness in India vs. in, 148–50; happiness levels study, 145–46; healthcare expenditures, 119, 480, 481, 481, 482; healthcare expenditures in, 381–82, 383; health expenditures as share of gross domestic product, in 2011, 386, 387; health policy in, 162; health technology assessment activities, 468; hospital choice in, 464; hospital ownership, 465; income inequality, in, 347; international medical graduates in, 318; life expectancy and infant mortality, 377, 484; mammography screening and breast cancer survival, 485, 486; managed care in, 461; market power of providers in, 390–91; market power trends in, 209, 209–12, 210; medicalizing trend in, 401; medical technology use, 467, 468; national health expenditures in, 270–71; number of uninsured in, selected characteristics, in 2012, 477; obesity rates, 487; patient cost sharing in, 404; per capita health expenditures, in 2011, 386; pharmaceutical advertising, 256; physician fee schedule, 471; physician payment, 466;
poverty levels, 136n11; provider payment mechanisms in, 456; public programs, 475, 476; public share of expenditures on medical services, in 2011, 388; quantity of specialized services in, 390; rationing policies, 366; redistribution in, 371; rise in deductibles in, 462; service wait times, 476, 479, 492, 499; smoking rates, 487, 488; source of payments, 1987–2010, 385; spending on pharmaceuticals in, 262; trends in for-profit hospital ownership in, 1980–2012, 232, 232–33; uninsured population in, 454; unit prices, 391, 392, 482; universal coverage in, 454; user charges, 493, 494; utilization rates, 479, 480; World Health Organization assessment, 474

Unit prices: healthcare expenditures and, 389–91, 392; in public sector, 393; ratio of US to Australian prices, 482


Universal healthcare system, 225, 351

University of California health benefits system: death spiral, 130

Unlicensed nonprofessional healthcare workers, 286, 287

Upcoding, 193, 242

Urban communities: physician location choices and, 320

Urban Institute, 187

US Health in International Perspective: Shorter Lives, Poorer Health (Institute of Medicine), 377

U.S. News & World Report, 74

Utilitarianism, 344, 364, 365; cardinal, 347; classical, 347, 357; definition of, 347; hybrid form of, 348; incremental, 348; ordinal, 345, 347, 348, 349–53, 357, 358, 365, 369, 378; problems with modern concept of, 348

Utility, 142; budget constraint, 11–12, 12; consumer choice and, 61–62; consumer optimum, 13–14, 14; explanation, 8–9; externality, 370; indifference curves, 9–11, 10; marginal, 8; maximization, 62–74, 81, 83–84; maximization model, 361–64; measurement of, 9; model, 301; qualities of, 74, 83; relative to the social norm, 150; theory, 368

Utilization: measures of, 479; of selected services, in 2011, 480

Utilization management, 202; cost containment and, 403, 407, 408; managed care and, 198–99; regional variation, 398; supply-side mechanisms, 192–205; techniques, 197; US healthcare system, 397

Utilization review, 120, 192, 197, 200, 504

Validity: of research studies, 101

Value-based insurance design, 127–28

Value-based purchasing, 194–95, 196, 409
Value of resources saved, 422, 424
van de Ven, Wynand, 461
van Doorslaer, E., 156, 348
VAP. See Ventilator-associated pneumonia
Variable costs, 26, 27, 426
VBID. See Value-based insurance design
Venkatapuram, S., 351, 360
Ventilator-associated pneumonia, 418, 419, 433, 439, 440; reducing, incremental cost-effectiveness ratio of four treatment options, 442–43
Vernon, J. A., 278
Vertical equity, 357
Vertical integration, 207–8, 209, 210, 212, 269
Veterans Health Administration, 406, 498
Viagra, 269
Viewpoints, 449; cost measurement and, 426; economic evaluation of, 426, 427, 427
Vioxx, 259
Visual analog scale, 429
Vladeck, Bruce, 163, 393
Voltaire, F.-M. A., 60
Volume performance standards, 471, 472
von Bismarck, Otto, 455
von Neuman, John, 228n10
VPSs. See Volume performance standards
Wages: change in long-run demand for labor, 296, 297; demand for healthcare labor and, 309, 309; determination of, 293; labor–labor substitution and, 296; labor–leisure trade-off and, 300–302, 301; registered nurse, 317, 323, 324–25
Wagstaff, Adam: health policy in Europe and United States, 162; health status/income relationship, 156; social justice, 348–49
Waiting list management, 492–93
Waste in medical care, 119–20
Wealth: concentration of, 347; entitlement theory and distribution of, 353; redistribution of, 345, 346, 348
Weighted life expectancy, 429
Weisbrod, Burton, 75, 76
Welfare economics, 48–49
Welfare loss: arguments, 109–19; from behaviors, 110–11, 123; coinsurance impact, 109, 120–23, 121; demand elasticity relationship, 113, 124–25, 125; from health insurance, 109–19, 129; RAND Health Insurance Experiment estimates, 95, 112
Welfare state: market reliance and reduced role of, 158
Welfarism, 83
Well-care services: price elasticities and, 125
Wellness: expenditures and focus on disease vs., 401
Wennberg, John, 119, 398
Wertheimer, A., 263, 357
Whellan, D., 247
White, C., 224
White, W. D., 218
Whitchall studies, of British civil servants, 153
WHO. See World Health Organization
“Whole hospital” exemption, 251
Wholey, Douglas, 217
Wickizer, T., 200
Wilkinson, R. G., 156
Williams, Bernard, 354
Williams, S. J., 266, 267
Willingness to pay, 422, 424, 430–32, 433, 445
Withholds, 200
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolf, Charles</td>
<td>50, 53</td>
</tr>
<tr>
<td>Women: physician choice of geographic location and</td>
<td>320</td>
</tr>
<tr>
<td>Work–life balance</td>
<td>321, 322</td>
</tr>
<tr>
<td>World Bank</td>
<td>499</td>
</tr>
<tr>
<td>World Health Organization</td>
<td>474, 499</td>
</tr>
<tr>
<td>Withholds</td>
<td>198, 199</td>
</tr>
<tr>
<td>WTP. See Willingness to pay</td>
<td></td>
</tr>
<tr>
<td>Wu, V.</td>
<td>224</td>
</tr>
<tr>
<td>Yip, W. C.</td>
<td>189</td>
</tr>
<tr>
<td>Yoshikawa, A.</td>
<td>467</td>
</tr>
<tr>
<td>Young, G. J.</td>
<td>248</td>
</tr>
<tr>
<td>Zaleski, P. A.</td>
<td>248</td>
</tr>
<tr>
<td>Zaslavsky, A.</td>
<td>330</td>
</tr>
<tr>
<td>Zero economic profits: surviving on</td>
<td>32</td>
</tr>
<tr>
<td>Zwanziger, J.</td>
<td>217, 223, 247</td>
</tr>
</tbody>
</table>